Potential Targets Other Than PSMA for Prostate Cancer Theranostics: A Systematic Review - Sorbonne Université
Journal Articles Journal of Clinical Medicine Year : 2021

Potential Targets Other Than PSMA for Prostate Cancer Theranostics: A Systematic Review

Paul Sargos
Eric Barret
  • Function : Author
  • PersonId : 1116883
Gaëlle Fromont-Hankard
Laurent Brureau
  • Function : Author
  • PersonId : 1110792
Gilles Créhange
  • Function : Author
  • PersonId : 1110793
Raphaële Renard-Penna
  • Function : Author
  • PersonId : 1116884
Gaëlle Fiard
Guilhem Roubaud
  • Function : Author
  • PersonId : 975634
Alain Ruffion
Morgan Rouprêt
  • Function : Author
  • PersonId : 1003501

Abstract

Background: Prostate-specific membrane antigen (PSMA) is not sufficiently overexpressed in a small proportion of prostate cancer (PCa) patients, who require other strategies for imaging and/or treatment. We reviewed potential targets other than PSMA for PCa theranostics in nuclear medicine that have already been tested in humans. Methods: We performed a systematic web search in the PubMed and Cochrane databases, with no time restrictions by pooling terms (“prostate cancer”, “prostatic neoplasms”) and (“radioligand”, “radiotracer”). Included articles were clinical studies. The results were synthetized by the target type. Results: We included 38 studies on six different targets: gastrin-releasing peptide receptors (GRPRs) (n = 23), androgen receptor (n = 11), somatostatin receptors (n = 6), urokinase plasminogen activator surface receptor (n = 4), fibroblast activation protein (n = 2 studies) and integrin receptors (n = 1). GRPRs, the most studied target, has a lower expression in high-grade PCa, CRPC and bone metastases. Its use might be of higher interest in treating earlier stages of PCa or low-grade PCa. Radiolabeled fibroblast activation protein inhibitors were the most recent and promising molecules, but specific studies reporting their interest in PCa are needed. Conclusion: Theranostics in nuclear medicine will continue to develop in the future, especially for PCa patients. Targets other than PSMA exist and deserve to be promoted.
Fichier principal
Vignette du fichier
jcm-10-04909-v2.pdf (436.21 Ko) Télécharger le fichier
Origin Publication funded by an institution

Dates and versions

hal-03431326 , version 1 (16-11-2021)

Identifiers

Cite

Mathieu Gauthé, Paul Sargos, Eric Barret, Gaëlle Fromont-Hankard, Jean-Baptiste Beauval, et al.. Potential Targets Other Than PSMA for Prostate Cancer Theranostics: A Systematic Review. Journal of Clinical Medicine, 2021, 10 (21), pp.4909. ⟨10.3390/jcm10214909⟩. ⟨hal-03431326⟩
49 View
122 Download

Altmetric

Share

More